{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:23:34Z","timestamp":1768256614240,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals International AG \u2013 Singapore Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Haemophilia A (HA) is associated with high clinical and healthcare burden. We developed an Excel-based model comparing current practice to improved management in severe HA patients currently managed on demand (OD). Outcomes included short- and long-term bleed events. Expected annual bleeds were estimated based on locally-derived OD annualised bleed rate (ABR), adjusted by relative prophylaxis-related ABRs (published literature). The objective of our study was to explore the impact of improving HA prophylaxis in target countries with limited published data (Algeria, Argentina, Chile, India, Malaysia, Mexico, Taiwan and Thailand). Bleed-related healthcare resource use (HCRU) and costs were estimated as a function of bleed type, with inputs obtained from local expert estimates. Clotting factor concentrates (CFC) consumption related to treatment and prophylaxis was estimated based on locally relevant dosing. CFC costs were not included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When 20% of OD patients were switched to prophylaxis, projected reduction in bleeds was estimated between 3% (Taiwan) through 14% (Algeria and India); projected reductions in hospitalisations ranged from 3% (Taiwan) through 15% (India). Projected HCRU-related annual cost savings were estimated at USD 0.45\u00a0m (Algeria), 0.77\u00a0m (Argentina), 0.28\u00a0m (Chile), 0.13\u00a0m (India), 0.29\u00a0m (Malaysia), 2.79\u00a0m (Mexico), 0.15\u00a0m (Taiwan) and 0.78\u00a0m (Thailand). Net change in annual CFC consumption ranged from a 0.05% reduction (Thailand) to an overall 5.4% increase (Algeria). Our model provides a flexible framework to estimate the clinical and cost offsets of improved prophylaxis. Modest increase in CFC consumption may be an acceptable offset for improvements in health and healthcare capacity in resource constrained economies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-023-06552-3","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:02:34Z","timestamp":1699621354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the impact of improved management of haemophilia a on clinical outcomes and healthcare utilisation and costs"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-1264","authenticated-orcid":false,"given":"Ravichandran","family":"Chandrasekaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-1901","authenticated-orcid":false,"given":"Mauro","family":"D\u00e1voli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulaiha","family":"Muda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-2037","authenticated-orcid":false,"given":"Uendy","family":"P\u00e9rez-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naouel","family":"Salhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6717-4975","authenticated-orcid":false,"given":"Nakul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-2148","authenticated-orcid":false,"given":"Ming-Ching","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HyeRyoung Haylee","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-3482","authenticated-orcid":false,"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0015-5219","authenticated-orcid":false,"given":"Veronica Soledad","family":"Soto-Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Solev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"9","key":"6552_CR1","doi-asserted-by":"publisher","first-page":"e0164009","DOI":"10.1371\/journal.pone.0164009","volume":"11","author":"CM Chen","year":"2016","unstructured":"Chen CM, et al. The utilization of Rehabilitation in patients with Hemophilia A in Taiwan: a Nationwide Population-Based study. PLoS ONE. 2016;11(9):e0164009.","journal-title":"PLoS ONE"},{"key":"6552_CR2","unstructured":"Hemophilia. W.F.o. Report on the Annual Global Survey 2019. Report on the Annual Global Survey 2020 October 2020 [cited 2022 Jan 11]; Available from: https:\/\/elearning.wfh.org\/resource\/report-on-the-annual-global-survey-2019\/."},{"key":"6552_CR3","doi-asserted-by":"crossref","unstructured":"Srivastava A et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020. 26 Suppl 6: p.\u00a01-158.","DOI":"10.1111\/hae.14046"},{"key":"6552_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12913-015-1134-3","volume":"15","author":"P Rocha","year":"2015","unstructured":"Rocha P, et al. Costs and utilization of treatment in patients with hemophilia. BMC Health Serv Res. 2015;15:484.","journal-title":"BMC Health Serv Res"},{"key":"6552_CR5","unstructured":"Hemophilia. W.F.o. World Bleeding Disorders Registry 2020. World Bleeding Disorders Registry 2020 2021 [cited 2022 Jan 11]."},{"key":"6552_CR6","unstructured":"Bank TW. World Development Indicators - The World by Income, Atlas method. World Development Indicators - The World by Income and Region 2021 1 July 2021 [cited 2022 11 Jan]; Available from: https:\/\/datatopics.worldbank.org\/world-development-indicators\/the-world-by-income-and-region.html."},{"issue":"3","key":"6552_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jfma.2021.07.017","volume":"121","author":"YC Chen","year":"2022","unstructured":"Chen YC, et al. Evolution of congenital haemophilia care in Taiwan. J Formos Med Assoc. 2022;121(3):582\u201391.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"6552_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","volume":"16","author":"J O\u2019Hara","year":"2018","unstructured":"O\u2019Hara J, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"6552_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/hae.13361","volume":"24","author":"K Khair","year":"2018","unstructured":"Khair K, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (advate in HaEmophilia A outcome database) study. Haemophilia. 2018;24(1):85\u201396.","journal-title":"Haemophilia"},{"issue":"4","key":"6552_CR10","first-page":"492","volume":"26","author":"L Aledort","year":"2020","unstructured":"Aledort L, et al. A retrospective observational study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. J Manag Care Spec Pharm. 2020;26(4):492\u2013503.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"6552_CR11","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1111\/hae.14052","volume":"26","author":"P Chowdary","year":"2020","unstructured":"Chowdary P, et al. Long-term safety and efficacy results from the phase 3b, open-label, multicentre continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 2020;26(4):e168\u201378.","journal-title":"Haemophilia"},{"issue":"3","key":"6552_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/hae.13753","volume":"25","author":"A Brekkan","year":"2019","unstructured":"Brekkan A, Degerman J, Jonsson S. Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. Haemophilia. 2019;25(3):408\u201315.","journal-title":"Haemophilia"},{"key":"6552_CR13","unstructured":"Malaysia MoH. Clinical Practice Guidelines 2018: Management of Haemophilia. Clinical Practice Guidelines 2018 2018 [cited 2022 Jan 11]; Available from: https:\/\/www.moh.gov.my\/moh\/resources\/penerbitan\/CPG\/CPG%20haemophilia%20201119.pdf."},{"issue":"8","key":"6552_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics. 2011;29(8):653\u201371.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"6552_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2516.2010.02367.x","volume":"17","author":"WS Liou","year":"2011","unstructured":"Liou WS, et al. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan. Haemophilia. 2011;17(1):45\u201354.","journal-title":"Haemophilia"},{"issue":"12","key":"6552_CR16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/13696998.2020.1828092","volume":"23","author":"L Graf","year":"2020","unstructured":"Graf L, et al. A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. J Med Econ. 2020;23(12):1493\u20138.","journal-title":"J Med Econ"},{"key":"6552_CR17","first-page":"CD014201","volume":"8","author":"OO Olasupo","year":"2021","unstructured":"Olasupo OO, et al. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Cochrane Database Syst Rev. 2021;8:CD014201.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6552_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","volume":"31","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186\u201392.","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06552-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:06:39Z","timestamp":1699621599000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6552"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06552-3","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"1 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All interviewees gave informed consent to take part in interviews. All methods were carried out in accordance with relevant guidelines and regulations. There was no requirement for review board sign offs for the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Competing interests: RC, MD, ZM, UP-L, Nao.S, MCS, DS, and VS received interview honoraria fees from Takeda. Nak.S and IS were employees of Takeda Pharmaceuticals International AG Singapore Branch at the time of analysis. HHS is a current employee of Takeda Pharmaceuticals International AG Singapore Branch. Nak.S and HHS report stock options held in Takeda Pharmaceutical Company Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}